L.Acidophillus and Bifidobacterium SPP Contribute in the Treatment of Chronic Hepatitis C Patients
Hepatitis C virus is a major leading cause of Liver pathogenesis. Probiotics showed a natural therapeutic activity
against liver disorders. The antiviral and the antibacterial responses to L. acidophilus and Bifidobacteria spp in patients with
chronic hepatitis C virus is a recommended study. Patients with chronic hepatitis C were treated with probiotics capsule that
contains L. acidophilus and Bifidobacterium spp. They administered one capsule per day for a month before HCV treatment,
blood and urine samples were collected before and after the given treatment and they were processed for a quantitative
estimation of HCV by PCR, identification of bacteria by VITEK2 system and 16S r RNA gene sequencing assay, moreover,
the estimation of antibacterial activity of probiotics, as well as counts of leukocytes, CD3 + T cells and CD56 + natural killer
cells. Administration of Probiotics capsule enhanced the treatment response rate to HCV treatments as IFN-α and ribavirin
by 25%. It had antibacterial activity against five species of the most common bacterial infections also It increased CD3 +
cells counts and CD56 + natural killer cells in chronic HCV patients. Administration of probiotics as a capsule before HCV
treatment can act as a supportive supplement with antiviral and antibacterial activities.
Index Terms - CD3 + ; CD56 + ; Hepatitis C virus; Lactobacillus acidophilus; Bifidobacterium bifidum.